PYPD vs. NEPH, PAVM, LYRA, MHUA, IINN, TTOO, MDAI, NMTC, GCTK, and FEMY
Should you be buying PolyPid stock or one of its competitors? The main competitors of PolyPid include Nephros (NEPH), PAVmed (PAVM), Lyra Therapeutics (LYRA), Meihua International Medical Technologies (MHUA), Inspira Technologies Oxy B.H.N. (IINN), T2 Biosystems (TTOO), Spectral AI (MDAI), NeuroOne Medical Technologies (NMTC), GlucoTrack (GCTK), and Femasys (FEMY). These companies are all part of the "surgical & medical instruments" industry.
PolyPid (NASDAQ:PYPD) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations.
PolyPid received 12 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 74.19% of users gave PolyPid an outperform vote while only 39.29% of users gave Nephros an outperform vote.
In the previous week, PolyPid had 3 more articles in the media than Nephros. MarketBeat recorded 11 mentions for PolyPid and 8 mentions for Nephros. PolyPid's average media sentiment score of 0.65 beat Nephros' score of 0.37 indicating that PolyPid is being referred to more favorably in the media.
Nephros has higher revenue and earnings than PolyPid. Nephros is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.
26.5% of PolyPid shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 4.1% of Nephros shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
PolyPid presently has a consensus target price of $14.00, suggesting a potential upside of 195.18%. Given PolyPid's higher possible upside, equities analysts clearly believe PolyPid is more favorable than Nephros.
PolyPid has a net margin of 0.00% compared to Nephros' net margin of -10.23%. Nephros' return on equity of -17.01% beat PolyPid's return on equity.
PolyPid has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.
Summary
PolyPid beats Nephros on 10 of the 16 factors compared between the two stocks.
Get PolyPid News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
